In A427 cells, Dactolisib abrogated VEGFA upregulation measured by supernatant ELISA. In human pancreatic CSCs, Dactolisib induced expression of 18 miRNAs and inhibited expression of 9 miRNAs compared with control. In Huh-7 cells, Dactolisib treatment increased IL-6 protein expression measured by ELISA. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Dactolisib abrogates VEGFA upregulation in lung cancer cells
Cell-based study · A427 cells [1]
A427 cells were treated with Dactolisib at 1 µM for 24 h, with DMSO as control. Supernatant ELISA measurements showed that treatment abrogated VEGFA upregulation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Dactolisib
The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.
Results > Targeting LAT1/mTOR overcomes wild-type KRAS-induced resistance (S85); Fig. 6 legend (S424)
ELISA-measured VEGFA levels in the supernatant: ELISA-measured VEGFA levels in the supernatant; comparator: DMSO — Results > Targeting LAT1/mTOR overcomes wild-type KRAS-induced resistance (S85); Fig. 6 legend (S424)
Dactolisib alters miRNA expression in human pancreatic CSCs
Cell-based study · human pancreatic CSCs [2]
Human pancreatic CSCs were treated with Dactolisib at 1 μM for 36 h. Compared with control, miRNA array analysis showed induced expression of 18 miRNAs and inhibited expression of 9 miRNAs.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 36 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Dactolisib; Compound label in the paper: NVP-BEZ 235
The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.
RESULTS > Regulation of microRNA network by NVP-BEZ-235 and/or NVP-LDE-225 in human pancreatic cancer stem cells (S86); Figure 5 legend (S281, S282, S283)
miRNA array (Affimetrix gene Chip) analysis: miRNA array (Affimetrix gene Chip) analysis; comparator: control — RESULTS > Regulation of microRNA network by NVP-BEZ-235 and/or NVP-LDE-225 in human pancreatic cancer stem cells (S86); Figure 5 legend (S283)
Dactolisib increases IL-6 protein expression in Huh-7 cells
Cell-based study · Huh-7 cells [3]
Huh-7 cells were pre-treated with Dactolisib at 100 nM for 24 h, with an untreated group as control. ELISA measurements showed increased IL-6 protein expression in treated cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM
- Exposure duration
- 24 h
- Method
- pre-treated
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Dactolisib; Compound label in the paper: NVP-BEZ 235
The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.
Materials and methods > Reagents (S4); Materials and methods > Enzyme-linked immunosorbent assay (S47); Results > NVP-BEZ235 increases the expression of IL-6 (S75); Fig. 3 legend (S128)
IL-6 protein levels in HCC cells measured by ELISA: IL-6 protein levels in HCC cells measured by ELISA; comparator: untreated group — Results > NVP-BEZ235 increases the expression of IL-6 (S75); Fig. 3 legend (S128)